Lv1
30 积分 2022-10-14 加入
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
2天前
待确认
Gefapixant in two randomised dose-escalation studies in chronic cough
2天前
已完结
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
3天前
已完结
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
10天前
已完结
Dioxotriazine derivatives as a new class of P2X3 receptor antagonists Part 1: Identification of a lead and initial SAR studies
24天前
已完结
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead
3个月前
已完结
皖公网安备34019202002308
